Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
topic
Journal for ImmunoTherapy of Cancer
Special collections
JITC
Commentary/Editorials
Commentary/Editorials
Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy
Bao-Dong
Qin
,
Xiao-Dong
Jiao
,
Ling-Yan
Yuan
,
Ying
Wu
,
Yan
Ling
,
Yuan-Sheng
Zang
Journal for ImmunoTherapy of Cancer
Apr 2024,
12
(4)
e008818;
DOI:
10.1136/jitc-2024-008818
Do galectins serve as soluble ligands for immune checkpoint receptors?
Nicolas I
Torres
,
Federico G
Baudou
,
Marco A
Scheidegger
,
Tomás
Dalotto-Moreno
,
Gabriel A
Rabinovich
Journal for ImmunoTherapy of Cancer
Apr 2024,
12
(4)
e008984;
DOI:
10.1136/jitc-2024-008984
Targeting of netrin-1 by monoclonal antibody NP137 inhibits the EMT in cancer
Xueli
Xia
,
Kai
Yin
,
Shengjun
Wang
Journal for ImmunoTherapy of Cancer
Apr 2024,
12
(4)
e008937;
DOI:
10.1136/jitc-2024-008937
SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials
Michael T
Lotze
,
Tricia
Cottrell
,
Carlo
Bifulco
,
Laura
Chow
,
Leslie
Cope
,
Sacha
Gnjatic
,
Holden T
Maecker
,
Joe
Yeong Poh Shen
Journal for ImmunoTherapy of Cancer
Mar 2024,
12
(3)
e008655;
DOI:
10.1136/jitc-2023-008655
Suppressive effects of obesity on NK cells: is it time to incorporate obesity as a clinical variable for NK cell-based cancer immunotherapy regimens?
Robert J
Canter
,
Sean J
Judge
,
Craig P
Collins
,
Daniel Jaeho
Yoon
,
William J
Murphy
Journal for ImmunoTherapy of Cancer
Mar 2024,
12
(3)
e008443;
DOI:
10.1136/jitc-2023-008443
Key role of CD4+ T cells in determining CD8 function during CAR-T cell manufacture
J Joseph
Melenhorst
,
Beatriz C
Oliveira
Journal for ImmunoTherapy of Cancer
Mar 2024,
12
(3)
e008723;
DOI:
10.1136/jitc-2023-008723
Toward standardization in bladder cancer clinical trials: Guidance from the SITC-IBCG expert panel
Amanda A
Myers
,
Ashish M
Kamat
,
Angela
Kilbert
,
Matthew D
Galsky
Journal for ImmunoTherapy of Cancer
Feb 2024,
12
(2)
e008508;
DOI:
10.1136/jitc-2023-008508
CARs are sharpening their weapons
Alice
Pievani
,
Marta
Biondi
,
Sarah
Tettamanti
,
Andrea
Biondi
,
Gianpietro
Dotti
,
Marta
Serafini
Journal for ImmunoTherapy of Cancer
Jan 2024,
12
(1)
e008275;
DOI:
10.1136/jitc-2023-008275
Perspectives on imaging and immunotherapy: a review series
Elisabeth GE
de Vries
,
Lawrence H
Schwartz
Journal for ImmunoTherapy of Cancer
Jun 2022,
10
(6)
e005006;
DOI:
10.1136/jitc-2022-005006
Sonic hedgehog pathway for the treatment of inflammatory diseases: implications and opportunities for future research
Marco
Palla
,
Luigi
Scarpato
,
Rossella
Di Trolio
,
Paolo Antonio
Ascierto
Journal for ImmunoTherapy of Cancer
Jun 2022,
10
(6)
e004397;
DOI:
10.1136/jitc-2021-004397
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
Special collections
COVID-19
(45)
Editor's choice
JITC
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Basic Tumor Immunology
(560)
Case Reports
(191)
Clinical Trials Monitor
(17)
Clinical/Translational Cancer Immunotherapy
(983)
Commentary/Editorials
(153)
Computational I-O
(4)
COVID-19 and Cancer Immunotherapy
(10)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(56)
Guidelines and Consensus Statements
(53)
Imaging and Immunotherapy
(9)
Immune Cell Therapies and Immune Cell Engineering
(242)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(437)
Liquid Biopsies
(10)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(151)
Reviews
(245)
The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer (SITC)
(1)
Open access
(5026)
Press releases
(2)
